ShockWave Medical, Inc. (SWAV)
| Market Cap | 7.98B |
| Revenue (ttm) | 130.11M |
| Net Income (ttm) | -52.83M |
| Shares Out | 35.03M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | 131.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,812 |
| Open | - |
| Previous Close | 227.05 |
| Day's Range | 216.84 - 219.41 |
| 52-Week Range | 66.09 - 237.76 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 210.67 (-2.8%) |
| Est. Earnings Date | Nov 9, 2021 |
About SWAV
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists ...
Financial Performance
In 2020, SWAV's revenue was $67.79 million, an increase of 57.92% compared to the previous year's $42.93 million. Losses were -$65.70 million, 28.5% more than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is 210.67, which is a decrease of -2.85% from the latest price.
News
Why Did Shockwave Medical Stock Gain 18% in August?
The medical device stock is growing even quicker than investors anticipated.
Shockwave Medical to Participate in Two Upcoming Virtual Investor Conferences
SANTA CLARA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular ...
This Healthcare Stock Grew Revenue by More Than 400% in the Second Quarter
Here's one innovative company you might want to put on your radar.
ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates
ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.
Why Shockwave Medical Surged as High as 10% Today
Top- and bottom-line beats plus raised guidance made for a very healthy stock on Monday.
Shockwave Medical Reports Narrower Than Expected Q2 Loss; Guides Above Consensus
Shockwave Medical Inc's (NASDAQ: SWAV) second-quarter FY21 sales were up 4-fold to $55.9 million beating the Wall Street consensus of $45.17 million. The growth was primarily driven by the launch of the...
Shockwave Medical (SWAV) Reports Q2 Loss, Tops Revenue Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 97.56% and 28.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ShockWave Medical: Q2 Earnings Insights
Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 98.21% year over year to ($0.01),...
Shockwave Medical Reports Second Quarter 2021 Financial Results
SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Why ShockWave Medical (SWAV) Might Surprise This Earnings Season
ShockWave Medical (SWAV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Ridiculously Overpriced Stocks That Could Crash in a Market Correction
Now may be the time to sell these stocks before their bubbles pop.
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shockwave Medical to Present at the Canaccord Genuity 41st Annual Growth Conference
SANTA CLARA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular d...
Shockwave Medical to Report Second Quarter 2021 Financial Results on August 9, 2021
SANTA CLARA, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
SVB Leerink Believes ShockWave Is Well-Positioned In Calcified Cardiovascular Market
SVB Leerink has initiated the coverage of ShockWave Medical Inc (NASDAQ: SWAV) with an Outperform rating and a $208 price target, implying an upside of approximately 25%. The analyst Danielle Antalffy n...
Where ShockWave Medical Stands With Analysts
ShockWave Medical (NASDAQ:SWAV) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1 Somewhat Bullish 0 1 1 0 Indifferen...
CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave's Coronary IVL
Provides Incremental Reimbursement in Hospital Outpatient Setting Provides Incremental Reimbursement in Hospital Outpatient Setting
Why Shockwave Medical Stock Jumped Today
The health tech specialist could save lives -- and deliver impressive growth to shareholders along the way.
Shockwave Medical Stock Jumps On Q1 Revenue Growth, Analyst Upgrades
Shockwave Medical Inc (NSDQ: SWAV) first-quarter FY21 sales more than double to $31.9 million beating the Wall Street consensus of $29.9 million. The growth was primarily driven by the launch of the cor...
Shockwave Medical (SWAV) Reports Q1 Loss, Tops Revenue Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -61.90% and 1.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: ShockWave Medical Q1 Earnings
Shares of ShockWave Medical (NASDAQ:SWAV) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 15.25% year over year to ($0.68), which missed the...
Shockwave Medical Reports First Quarter 2021 Financial Results
SANTA CLARA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calci...
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
ShockWave Medical's Earnings Outlook
ShockWave Medical (NASDAQ:SWAV) releases its next round of earnings this Monday, May 10. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.
CMS Proposes Additional Payment for Shockwave's Coronary IVL in Hospital Inpatient Cases
New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule